Ten niessee 37232 AB S T R A C T High levels of beta receptor agonist have previously been showin to dowvn-regulate beta receptor density on circulating leukocytes in man; however, the factors controlling receptor density under physiological conditionis have not previously beein de-fined. To determine whether beta receptor density is normally down-reguilated by circulating, physiological levels of catecholamlines we have examined the relationship between receptor density and catecholamine levels. Urinary epinephrine and norepinephrine were significantly reciprocally correlated to lymphocyte receptor density. A similar relationship existed between beta receptor density and supine plasma epinephrine, norepinephrine, upright epinephrine, and norepinephrine levels. Change in sodium intake from 10 to 400 meq/d cauised a 52% increase in lymphocyte and a 48% increase in polymorphonuclear beta receptor density. The changes in receptor density were accompanied by an increase in the sensitivity to isoproterenol measured as a fall in the dose of isoproterenol required to raise the heart rate by 25 beats per minute. Beta receptor density on both lymphocyte and polymorphonuclear cells was significantly correlated to the cardiac sensitivity to isoproterenol.
INTRODUCTION
The uise of radiolabeled agonists and antagonists of high specific activity has allowed the development of radioligand binding assays for the detailed study of receptor functioin (1) (2) (3) (4) (5) (6) (7) (8) (9) . The recent application of this technique to the beta adrenergic receptor on human leukocytes has allowed this to be extended to man. High levels of beta adrenergic agonists have been shown in vitro (10, 11) to result in a reduction, or down-regulation of beta adrenergic receptor density, whereas the in vivo administration of high doses of adrenergic agonists, for example in the treatment of asthma (12) (13) (14) (15) , or the high levels of catecholamines in patients with pheochromocytoma (15) result in reduced beta receptor density (16) and diminished cyclic AMP generation by leukocytes in response to isoproterenol. It has, therefore, been suggested that pharmacological doses of catecholamines will result in down-regulation of receptor density with consequient reduction in the sensitivity to adrenergic agents (17) .
It is also possible that changes in beta receptor density accounit for the considerable interindividual variability in the response to both beta receptor agonists and antagonists (18) . For example Schocken and Roth (19) found that leukocyte beta receptor density was reduced in elderly patients, while Vestal et al. (20) found that elderly subjects had a reduced cardiac chronotropic response to both beta receptor agonist and antagonist. This raises the question of whether receptor density, measured on human leukocytes, might reflect receptor density in other less accessible tissues such as the heart and hence whether changes in leukocyte receptor density are reflected in changes in the cardiac chronotropic response to isoproterenol. In spite of the evidence that pharmacological doses of catecholamines can reduce receptor fumnction in man, the factors controlling receptor ftinction in normal man have not been defined. We postulated that receptor density is normally regulated by the degree of sympathetic tone, thus increased sympathetic tone should result in increased production of catecholamines and down-regulation of beta adrenergic receptors. If beta adrenergic receptors are normally down-regulated by physiological levels of catecholamines then blockade of these receptors by administration of a beta receptor antagonist, such as propranolol, should result in release of this down-regulation and a consequent increase in receptor density. If this increase in receptor density is due to blockade of down-regulation then the higher the catecholamines and the greater the down-regulation prior to propranolol, the larger will be the rise in receptor density following propranolol treatment. The possibility of such an increase in receptor density during propranolol treatment has led some (17, 18) to suggest this as an explanation for the propranolol withdrawal syndrome that has been described following abrupt propranolol withdrawal and has been associated with increased frequency of angina and even myocardial infarction (21) . This syndrome has many of the features of a hyperadrenergic state and it has been suggested that hypersensitivity to beta receptor agonists can occur during the period following propranolol withdrawal (21, 22, 23) . In a previous study after 8 d of propranolol treatment beta receptor density remained elevated for 48 h after stopping propranolol suggesting that this might explain the previously described hyperadrenergic state (24) . However, the relevance of 8 d of propranolol treatment to the usual therapeutic situation when propranolol is administered chronically, is unclear.
Circulating levels of catecholamines can be altered by stimuli which activate the sympathetic nervous system (25) . By means of such stimuli, it should be possible to increase endogenous norepinephrine and epinephrine levels and thus determine if significant down-regulation of beta receptor density is achieved by physiological levels of catecholamines. For purposes of this study it seemed prudent to utilize a stimulus of prolonged duration in order that there would be sufficient time for regulation of receptor density to occur. Restriction of dietary sodium increases plasma norepinephrine (25, 26, 27) while there is a trend toward reduced plasnma norepinephrine following excessive sodium intake (26, 27) . Parallel changes in plasma epinephrine probably occur. These changes in catecholamine levels are likely due to reductioni and expansioni, respectively, of blood volume. The volume reduction of low sodium intake results in baroreceptor-nmediated activation of both the sympathetic aind renin systems. Volume expansion results in the opposite effects althouigh they are less marked in degree (26) . Dietary sodium contents of 10, 150, and 400 meq were selected as low, medium, and high salt intakes for purposes of this study.
We therefore studied the relationship between beta receptor density on circulating leukocytes and sympathetic activity as meastured by catecholamine levels in a group of normal volunteers. The effect of beta blockade and altered sodium balance were assessed in terms of three variables determining or reflecting sympathetic activation: (a) plasma catecholamine levels, (b) leukocyte beta receptor density, and (c) cardiac sensitivity to isoproterenol.
MET11ODS
Subjects. A total of' 22 normotensive male volunteers aged 22-38 yr anid 2 patienits with pheochromocytoma participated in the study. The protocol had previously been approved by the Vanderbilt University Comimittee for the Protection of Humian Subjects. All of the subjects, with the exception of the two wvith pheochromocytoma, had no abnormalities on an admuissioni screeninig that incltuded physical examination, electrocardiogramii, clhest x-ray, hemlatology profile, liver, and renal functioni tests. None of' them had taken any medication for at least a month preceding the study and none received medication except propranolol duriing the period of the study.
Seven of' the subjects received each of three diets containing 10, 150, anid 400 me(q of soditunm per day for 10 d. The order in which the diets were administered was determined by chance and the stuidies were separated by 21.7+ 1.1 d. On the last 2 d of each diet between 8:30 and 9.30 a.m. a blood sample was taken after the stubject had been supine for at least 30 min, throuigh an indwellinig cannula that had been in place for at least 20 min ffor the measurement of leukocyte beta receptor density as described below and for epinephrine and norepinephrine by radioenzymatic assay (28) . A further blood sample vas takeni after the subject had been standing for 10 mni and the conicentrationi of' epinephrine and norepiniephrinie determined. On the last 2 d of the diet urine was collected f'or the measturement of'catecholamines and sodium. The subjects were weighed and their blood pressure and pulse measured b)oth suipine and after they had been upright for 2 min at the end of each diet. Mean arterial pressure was determined as the (liastolic presstire pluis one third of the puilse pressture.
On the last day of' eaclh diet the cardiac sensitivity to isoproterenol vas determnined. Increasing doses of the beta agonist isoproterenol were administered and the rise in heart rate produced by each dose plotted against the logarithm of the dose of isoprotereniol. At least five points on the loglinear portion of the dose-response curve were examined for each subject and the best-fit line determined by linear regressioni analysis. The dose of' isoproterenol required to raise the heart rate by 25 beats per miniute (125)1 was deterAbbreviatiotns used int thtis paper: Bmax, beta receptor density; DHA, [3H]dihydroalprenolol; I25, isoproterenol requiired to raise heart beat rate by 25 beats per minute. mined from this line. The I25 is a measure of cardiac resistanlce to isoproterenol with increasing values implying increased resistance and lower values implying increased sensitivity to isoproterenol.
16 of the subjects received propranolol 80 mg three times daily for 4 wk. Two of the subjects withdrew after 1 wk of propranolol therapy because of insomnia, but their data is included. Blood samples were taken prior to propranolol treatment, weekly during propranolol treatment, and at 24, 48, 72, and 96 h after stopping propranolol for the measurement of leukocyte beta receptor density, plasma norepinephrine, epinephrine (28) , and plasma propranolol (29) . The subjects' weight, blood pressure, and heart rates both standing and supine were determined on each day as described above. 24-h urine collectioins were also made at these times aind urinary catecholamiiine excretion measured.
The lymphocytes and polymorphonuclear cells were isolated from 60 ml of fresh blood anticoagulated with EDTA by centrifugation on Ficoll-Hypaque density gradients (30) . The blood was centrifuged at 200 g for 15 min at room temperature and the platelet-rich plasma pipetted off (31) . The buffy coat plus 7 ml of erythrocytes was then wvashed with 40 ml 0.01 NI phosphate-buffered saline (pH 7.4) at 37°C and processed to isolate and separate the lymphocytes and polymorphonuclear cells. Contaminating erythrocytes were removed from the polymorphonuclears by a brief exposure to 0.2% saline (16) . To prepare the particulate fraction, the cells were lysed for 30 min in 0.2% saline at 40C, centrifuged for 15 min at 400 g at 40C, resuspended in 5% glycerol, frozen for 1 min in a dry-ice acetone bath, and quickly thawed at room temperature. The particulate fraction was recovered by centrifugation at 1,000 g for 20 min at 40C and washed with Tris buffer pH 7.4 at 4°C. Particulate fractions were resuspended in Tris buffer (Tris-HCl 75 mM, NMgCl2 15 mM, pH 7.4) at 370C at a final protein concentration of 1-3 mg/ml by gently homogenizing in a glass Teflon homogenizer.
Beta receptor density of particulate fractionis was then measured uising [3H]dihydroalprenolol (DHA) (51 Ci/mmol, New England Ntuclear, Boston, Mass.) as described b)y Williams aind Galant (7, 8) . The incubation included 0.1 mM phentolamine, 0.3 mM catechol, and 0.1 mM ascorbic acid to 
RESULTS
Urinary sodium output on the three diets is shown in Table I and was close to the calculated intake demonstrating the subject's compliance with the diet. There was a significant fall in weight (Table I) between the 150-and 10-meq sodium diet. This was accompanied by a significant rise in the heart rate response to standing and a fall in both supine and upright systolic and mean upright blood pressure (Table I) . The effect of changes in sodium intake on the urinary excretion of epinephrine and norepinephrine is shown in Table II . Urinary norepinephrine increased by 31% on the 10-meq sodium diet compared with the 400-meq soditum diet. Urinary epinephrine was significantly higher when the stubjects were taking 150 compared witlh 400 meq of sodium per day. Plasma norepinephrine and epinephrine also increased as sodium intake decreased (Table II) .
Beta receptor density (Bmax of DHA binding) on lymphocytes was 52% higher on the 400-meq sodium intake compared with the 10-meq diet (Table II) . Bmax on polymorphonuclear cells increased 48% from 37.0±3.6 (SEM) to 54.3+4.7 fmol/mg protein on the 400-meq Na/d diet compared to the 10-meq Na/d diet (Table II) .
A significant relationship was found between the logarithm of urinary epinephrine (r = -0.527, P < 0.001) norepinephrine (r = -0.327, P < 0.02) and Bmax on lymphocytes. Lymphocyte receptor density was also significantly correlated to supine (r = -0.482, P < 0.001) and upright (r = -0.460, P < 0.001) epinephrine and more weakkly to supinie (r = -0.306, P < 0.05) and upright norepinephrine (r = -0.364, P < 0.02). The Bmax on polymorphonticlear cells was significantly correlated with supine epinephrine (r = -0.348,P < .01), upright epinephrine (r = -0.349, P < .01), supine norepinephrine (r = -0.341, P < 0.02), and upright norepinephrine (r = -0.277, P < 0.05). The correlations of Bmax of DHA binding on lymphocytes with upright norepinephrine, supine epinephrine, and upright epinephrine were significant with or without the patients with pheochromocytoma. The propranolol concentrations in subjects during treatment were 130+25.3 ng/ml. That these concentrations achieved beta blockade was shown by the reduction in the rise in pulse rate on standing (Table III) which was 21+3.0 beats/min before propranolol and 12.4±1.2 on propranolol therapy. There was also the expected fall in supine and upright pulse rate and in the rate pressure product (Table III) . Urinary norepinephrine was significantly elevated 1 wk after starting propranolol therapy, whereas urinary epinephrine was significantly increased in the 24 h after stopping propranolol treatment (Table IV) .
Propranolol administration resulted in a 27% increase in lymphocyte beta receptor density (Table IV) after 1 wk of treatment. Similar changes were seen in polymorphonuclear beta receptor density, which increased 29% after 1 wk of propranolol treatment (Table IV) . This increase persisted over the 4 ing) over the 4-wk period of propranolol treatment was norepinephrine (r = 0.627, P < 0.05) and 24 h urinary correlated with the concentrations of plasma and norepinephrine (r = 0.735, P < 0.05). urinary epinephrine and norepinephrine present Bmax following propranolol withdrawal is shown in before propranolol treatment was started. On poly-Table IV. Receptor density had returned to base line or morphonuclear cells there was a significant positive pretreatment levels by 48 h. At 24 h after withdrawal correlation between supine plasma norepinephrine there was considerable variability in the degree of in-(r = 0.839, P < 0.001; Fig. 2 ) epinephrine (r = 0.735, crease in Bmax still present. This variation was related P < 0.05) measured before propranolol treatment and to the magnitude of the increase in Bmax while on prothe increase in Bmax of DHA binding on polymorpho-pranolol. There was a significant positive correlation nuclear cells during the 4 wk of propranolol treatment. between the Bmax on polymorphonuclear cells at 24 h The rise in Bmax on lymphocytes in response to propran-after propranolol withdrawal and the average Bmax olol treatment also correlated with initial supine plasma during propranolol treatment relative to the Bmax before propranolol treatment (r = 0.812, P < 0.005). There was no evidence of overshoot or elevation of receptor density above pretreatment receptor density nor was there evidence of either heart rate or blood pressure elevation above pretreatment levels.
The cardiac sensitivity to isoproterenol was measured as the dose of isoproterenol required to raise the heart rate by 25 beats per minute on 10-, 150-, and 400-meq sodium diets and the results are shown in Table II. There was a significant increase in sensitivity to isoproterenol, that is a reduction in the dose of isoproterenol required to raise the heart rate by 25 beats per minute, when the subjects received 400-meq sodium diets compared with 150-and 10-meq diets. This increase in sensitivity to isoproterenol accompanied the increase in leukocyte beta receptor density on the high salt diet and resulted in a significant correlation between I25 and the Bmax on lymphocytes (Fig. 3 ) and polymorphonuclear cells (Fig. 4) . DISCUSSION Although leukocyte receptor density has been extensively studied the factors controlling receptor density and accounting for the large interindividual variation in receptor density have not been determined. We have shown that receptor density is reciprocally related to circulating catecholamine concentrations and also to 24-h urinary catecholamine levels, which reflect sympathetic function throughout the day. It is of interest to note that although the relationship existed for both epinephrine and norepinephrine it was stronger for epinephrine. This is Although leukocyte adrenergic receptors have been extensively studied in both man and animals (17) the assumption that changes in leukocyte receptor density reflects adrenergic function in other less accessible tissues has not been tested in man. By varying sodium intake within a group of individuals we were able to alter their catecholamines within the physiological range. This increase in sodium intake reduced catecholamine levels and by reducing down regulation allowed receptor density to increase with a resultant increase in sensitivity. The correlation between leukocyte beta receptor density and cardiac sensitivity to isoproterenol validates the use of this technique in studying adrenergic receptor function in man.
Although pharmacological doses of adrenergic agents have previously been shown to alter receptor function in man (12) (13) (14) (15) (16) this study demonstrates that changes in catecholamine levels within the physiological range are associated with alteration in receptor density and sensitivity to adrenergic agents.
By showing that Bmax on leukocytes correlate with changes in cardiac responsiveness to isoproterenol, and by demonstrating that receptor density in vivo is controlled by catecholamine levels, we have confirmed the utility of measuring leukocyte receptor density. In the future it should be possible, by combining measurement of Bmax and circulating agonist concentrations to define groups of patients with abnormal receptor regulation.
